Clinical trials: Idiopathic Refractory Scleritis

Idiopathic Refractory Scleritis

Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)

• Withdrawn
• Age: 18 years and older
• Phase 3

This study will evaluate the Efficacy and Safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis.

Trial name

CIRIS (NCT03088293)

Testing

Infliximab, Cyclophosphamide

Sponsor

Hospices Civils de Lyon